These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21593456)

  • 21. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
    Michos ED; Blumenthal RS
    J Am Coll Cardiol; 2009 Mar; 53(11):931-5. PubMed ID: 19281922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Was the FDA misled by JUPITER?
    MacDonald GP
    J Am Osteopath Assoc; 2010 Aug; 110(8):424-5. PubMed ID: 20805547
    [No Abstract]   [Full Text] [Related]  

  • 23. [JUPITER no support of changed guidelines for cardiovascular prevention. Moderate absolute risk reduction and uncertain long term effects].
    Håkansson J
    Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1460-1. PubMed ID: 19579433
    [No Abstract]   [Full Text] [Related]  

  • 24. Rosuvastatin in patients with elevated C-reactive protein.
    Pierard LA
    N Engl J Med; 2009 Mar; 360(10):1040; author reply 1041-2. PubMed ID: 19271277
    [No Abstract]   [Full Text] [Related]  

  • 25. JUPITER: wake up and smell the coffee--the absolute and relative merits of statin use.
    Jackson G; Citrome L
    Int J Clin Pract; 2009 Mar; 63(3):347-8. PubMed ID: 19222618
    [No Abstract]   [Full Text] [Related]  

  • 26. What else does the JUPITER trial add regarding C-reactive protein and cardiovascular disease?
    Lin GM; Li YH; Chu KM; Han CL
    Int J Cardiol; 2011 Jun; 149(3):387. PubMed ID: 21450359
    [No Abstract]   [Full Text] [Related]  

  • 27. Rosuvastatin in patients with elevated C-reactive protein.
    Jenny-Avital ER
    N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271275
    [No Abstract]   [Full Text] [Related]  

  • 28. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels.
    Choudhry NK; Patrick AR; Glynn RJ; Avorn J
    J Am Coll Cardiol; 2011 Feb; 57(7):784-91. PubMed ID: 21310313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Jupiter to Earth: CRP promotes atherothrombosis.
    Jialal I; Devaraj S
    Metab Syndr Relat Disord; 2009 Feb; 7(1):1-3. PubMed ID: 19183073
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER.
    Slejko JF; Page RL; Sullivan PW
    Curr Med Res Opin; 2010 Oct; 26(10):2485-97. PubMed ID: 20828360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. JUPITER, rosuvastatin, and the European Medicines Agency.
    Ridker PM; Glynn RJ
    Lancet; 2010 Jun; 375(9731):2071. PubMed ID: 20494436
    [No Abstract]   [Full Text] [Related]  

  • 32. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
    Fonseca FA; Izar MC
    Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rosuvastatin in patients with elevated C-reactive protein.
    Gibbons RJ
    N Engl J Med; 2009 Mar; 360(10):1038; author reply 1041-2. PubMed ID: 19264695
    [No Abstract]   [Full Text] [Related]  

  • 34. Serum levels of C-reactive protein in patients with stable coronary artery disease: JUPITER in perspective.
    Saely CH; Rein P; Vonbank A; Drexel H
    Int J Cardiol; 2010 Oct; 144(3):448-9. PubMed ID: 19351576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study stirs debate about statin use in those without high cholesterol.
    Mayo Clin Womens Healthsource; 2009 Apr; 13(4):3. PubMed ID: 19255535
    [No Abstract]   [Full Text] [Related]  

  • 36. Rosuvastatin in patients with elevated C-reactive protein.
    Chan PS; Nallamothu BK; Hayward RA
    N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271273
    [No Abstract]   [Full Text] [Related]  

  • 37. The Jupiter trial--new territory for statins?
    Wheeler DC
    Nephrol Dial Transplant; 2009 Jul; 24(7):2036-7. PubMed ID: 19541666
    [No Abstract]   [Full Text] [Related]  

  • 38. Rosuvastatin in patients with elevated C-reactive protein.
    Koller MT; Bucher HC; Steyerberg EW
    N Engl J Med; 2009 Mar; 360(10):1041; author reply 1041-2. PubMed ID: 19271276
    [No Abstract]   [Full Text] [Related]  

  • 39. [Less vascular risk with rosuvastatin in elevated CRP].
    Bredie B
    Ned Tijdschr Geneeskd; 2009 Feb; 153(6):245. PubMed ID: 19271446
    [No Abstract]   [Full Text] [Related]  

  • 40. [Statin cuts cardiovascular risk in half].
    Einecke D
    MMW Fortschr Med; 2008 Dec; 150(49-50):12-3. PubMed ID: 19133364
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.